Trends in Biopharmaceutical Contract Manufacturing

摘要

Over the past decade, the demand for biopharmaceutical contract manufacturing services grew at a compound annual rate of 13% per year. During this time, pharmaceutical and biotechnology companies have increasingly relied on contractors for the production of their biologic drug substances. There are many reasons for pharmaceutical and biotechnology companies to use contract manufacturing organizations (CMOs) to produce their biologic drug substance, including limit risks, reduce the overall investment required to bring a new drug product to market, gain access to markets or technologies, and greater flexibility. In the future, large pharmaceutical and biotechnology companies will increasingly rely on CMOs for the production of their biopharmaceutical drug substances. As a result of thesetrends, the market for biopharmaceutical contract manufacturing services is expected to reach $3.1 billion by 2016.